Dermatologists should consider ordering a 31-gene expression profile test to determine metastasis risk in patients with newly diagnosed cutaneous malignant melanoma, according to a study.
“A 31-gene expression profile (31-GEP) test that predicts metastatic risk in patients with cutaneous malignant melanoma (CMM) has previously been validated and is available for clinical use,” Alexander Witkowski, MD, PhD, of the department of dermatology at Oregon Health & Science University, and colleagues wrote.
They noted that the test allows clinicians to assign patients to a low- or